Akari Therapeutics, Plc
AKTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.6M
$8.39
▼ -6.15%
P/E
—
Mkt Cap
$9.6M
52-Wk Range
$3.02–$44.40
52-Week Range
$3.02 - $44.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 80.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Second-generation complement inhibitor technology with dual mechanism of action
- Addressing unmet medical needs in rare disease markets with high barriers to entry
- Strong intellectual property portfolio protecting nomacopan formulations
- Strategic focus on high-value, niche therapeutic areas with premium pricing potential
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical trial progression for nomacopan across multiple rare disease indications
Value
Valuation data unavailable
Momentum
Falling
-45.8% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying AKTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Dec 4, 2026
AUG 13, 2026
Reported EPS of -$1.04 vs -$1.04 consensus (0.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Sep 16, 2026
vs Industry
How AKTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related